3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
7
Thoracic
2
Head & Neck
2
Gastrointestinal
1
Breast
1
Conditions
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
59
Nivolumab
34
Cyclophosphamide
21
fludarabine
15
Paclitaxel
12
Ipilimumab
12
atezolizumab
11
Specimen Handling
11
Magnetic Resonance Spectroscopy
10
Carboplatin
10
Docetaxel
9
Cisplatin
9
Gemcitabine
8
Biopsy
8
durvalumab
7
aldesleukin
7
Radiosurgery
7
Interleukin-2
7
Bevacizumab
7
cemiplimab
6
Pemetrexed
6
fludarabine phosphate
5
avelumab
5
Radiotherapy
5
Drug Therapy
5
spartalizumab
4
epacadostat
4
enzalutamide
4
Taxes
4
Sirolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Toll-Like Receptor 1
×
Gastrointestinal
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled